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A novel approach to postmastectomy radiation therapy using scanned proton
beams
Abstract
Purpose: Postmastectomy radiation therapy (PMRT), currently offered at Massachusetts General
Hospital, uses proton pencil beam scanning (PBS) with intensity modulation, achieving complete target
coverage of the chest wall and all nodal regions and reduced dose to the cardiac structures. This work
presents the current methodology for such treatment and the ongoing effort for its improvements.
Methods and Materials: A single PBS field is optimized to ensure appropriate target coverage and heart/
lung sparing, using an in-house-developed proton planning system with the capability of multicriteria
optimization. The dose to the chest wall skin is controlled as a separate objective in the optimization.
Surface imaging is used for setup because it is a suitable surrogate for superficial target volumes. In
order to minimize the effect of beam range uncertainties, the relative proton stopping power ratio of the
material in breast implants was determined through separate measurements. Phantom measurements
were also made to validate the accuracy of skin dose calculation in the treatment planning system.
Additionally, the treatment planning robustness was evaluated relative to setup perturbations and patient
breathing motion. Results: PBS PMRT planning resulted in appropriate target coverage and organ sparing,
comparable to treatments by passive scattering (PS) beams but much improved in nodal coverage and
cardiac sparing compared to conventional treatments by photon/electron beams. The overall treatment
time was much shorter than PS and also shorter than conventional photon/electron treatment. The
accuracy of the skin dose calculation by the planning system was within ±2%. The treatment was shown
to be adequately robust relative to both setup uncertainties and patient breathing motion, resulting in
clinically satisfying dose distributions. Conclusions: More than 25 PMRT patients have been successfully
treated at Massachusetts General Hospital by using single-PBS fields. The methodology and robustness
of both the setup and the treatment have been discussed.
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A novel approach to post-mastectomyradiation therapy
using scannedproton beams
Running title: Post-mastectomyradiationtherapyusingIMPT

Abstract

Purpose:Post-mastectomyradiation therapy (PMRT) is currently offered at the
institution using proton pencil beam scanning (PBS) with intensity modulation,
achievingcompletetargetcoverageof chestwall and all nodalregionsand reduced
doseto thecardiacstructures.This work presentsthecurrentmethodologyin placefor
suchtreatment,andtheon-going effort for its improvements.

Materials and methods:A singlePBSfield is optimizedto ensureappropriatetarget
coverageandheart/lungsparing,usingan in-housedevelopedprotonplanningsystem
with thecapabilityof multi-criteriaoptimization(MCO). Thedoseto chestwall skin is
controlled as a separateobjective in the optimization.Surfaceimagingis used for
setupas it is a suitablesurrogatefor superficialtargetvolumes.In orderto minimize
the effect of beamrangeuncertainties,the relative protonstoppingpowerratio (RSP)
of the material in breastimplantswas determinedthrough separatemeasurements.
Phantommeasurements
were also performedto validate the accuracyof skin dose
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calculation in the treatment planning system. Additionally, the treatment
planningrobustnesswas evaluatedagainstsetupperturbationsand patientbreathing
motion.

Results:PBS PMRT planningresultsin appropriatetargetcoverageas well as organ
sparing, comparableto treatmentsby passive scattering (PS) beams, but much
improvedin nodalcoverageandcardiacsparingcomparedto conventionaltreatments
by photon/electronbeams.The overall treatmenttime is much shorterthan PS,and
alsoshorterthanconventionalphoton/electrontreatment.Theaccuracyof theskin dose
calculationby the planningsystemis within ±2 %. The treatmentwas shown to be
adequatelyrobust against both setupuncertaintiesand patient breathing motion,
resultingin clinically satisfyingdosedistributions.

Conclusions:Over 25 PMRT patients have been successfully treated at the
institutionusingsinglePBSfields. The methodologyandrobustnessof both the setup
andthetreatmentweredemonstrated.

1 Introduction
Radiationtherapyhasbeenan effectivetool in the managementof breastcancer[1].
There are, however, concernsof late cardiac effects due to this treatment[ 2-8].
Minimizing the dose to the heart has been the focus of various treatment
improvementsincluding the use of heart blocks, CT-based planning, intensity
modulation, etc. [9]. Breath holding is one of the most effective techniquesin
2

reducingthe volumeof cardiactissuesfor conventionalphotontherapyusingtangent
fields andis currentlypracticedin manyinstitutions[10, 11], eventhoughits efficacy
hasrecentlybeenquestioned[12].
Despitestheseefforts, target volumescannotbe fully coveredwhile avoiding the
cardiactissuesfor manypatients.This is true for post-mastectomyradiationtherapy
(PMRT) with involvedinternalmammarynodes(IMN) for patientswith unfavorable
cardiacanatomy.The standardPMRT treatmenttechniqueusesa combinationof
photon/electronbeamswith up to five fields involving multiple field matching.The
optimization of such complex plans usually takes tremendousefforts in order to
balance between IMN

coverage, heart dose, hot

and

cold

spots.

Thedistinctivephysicalpropertiesof theprotonbeam,i.e. theBraggpeak,offersnew
possibilitiesin meetingthe challengesof PMRT. Severaltreatmentplanningstudies
have demonstratedsignificant dosimetric advantagesfor reducing heart and lung
doseswhile improving targetcoverage[13-17]. Thus, a proton PMRT clinical trial
was startedat theinstitutionand early outcomesshowedthat the treatmentwas well
tolerated[18].
A first setof patientswastreatedwith enfacepassivelyscattered(PS)protonbeams.
While the treatmentsachievedthe primary goalsof minimizing the doseto the heart
andlungs,andadequatelycoveringthe chestwall andinvolvednodes,severalaspects
of the treatmentwere less than ideal. The largesteffective field size (± 2 % dose
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homogeneity)for a PS beamis 22 cm in diameter.Most patientsthereforerequired
abuttingfields, one for chestwall/IMN and one for the superiornodal targets.The
matchlinebetweenthe two fields hadto be feathered,requiringtwo setsof hardware
(apertureand compensators).The overall treatmentgenerally took 30

minutes.

Moreover, the lack of intensity modulation resulted in full skin dose and dose
heterogeneities.
Protonpencilbeamscanning(PBS)is graduallybecomingavailablein protontherapy
centersworldwide.Two of the mostdistinctivefeaturesof PBS,intensitymodulation
andlargertreatmentfield size,arecritical elements for improvingprotonPMRT.This
work describesthe institutionPBSPMRT treatmenttechnique,its validation,aswell
astheongoingeffortsperformedto ameliorateits delivery.
2 Materials and methods
2.1 Patient setupand CT scanning
The PMRT patients were positioned on a breast board used for conventional
photon/electrontreatmentwith botharmsup abovetheir head.Thebreastboardangle
wasraisedto its limit to help with the surfaceimagingsystemusedfor patientsetup.
Various improvementswere deployedin order to minimize setupposition errors:a
head& neckheadcup wasusedto bettercontrolthe neckposition;handgrips anda
chin strapwereprovidedto furtherimmobilizethearmandchin positions.Figure1(a)
showsthe setupat the institution with the patient’s arms raisedabovetheir head.
4

Figure1(b) also showsthe samepatientin a arm down position.For somepatients,
this akimbo position was the only choicefor radiotherapydue to someimmobility
factors. As

later discussed, this position presents convenient aspects.

A helicalCT scanof the patientat quietrespirationwasacquiredusinga GE Medical
Systems™LightSpeedRT16or DiscoveryCTR590RTat 140 kV and500 mA with
2.5 mm slicethickness.
2.2 Treatment planning
Similar delineationof the targetvolumesandorgansat risk (OAR) areperformedfor
PBS treatmentas for conventionalphoton therapy. The target (CTV) is usually
composedof the whole chestwall and lymph nodesconsideredat risk for harboring
disease(axillary, supraclavicular,internalmammary).
Planningobjectivesaregenerallydefinedasfollow:
45 Gy(RBE)to the chestwall andall nodesfollowed by a 5.4 Gy(RBE)boostto the chestwall and
internalmammarynodes(IMN)
48 Gy(RBE)maxdoseto thechestwall’s skin ( 3 mm superficial)
3 Gy(RBE)maxdoseto theleft anteriordescendingcoronaryartery(LAD)
5 Gy(RBE)maxdoseto theheart’sleft ventricle
1 Gy(RBE)meanheartdose
15 % V for eachlung
20

42 Gy(RBE)maxdoseto thethyroid

5

40 Gy(RBE)max doseto theesophagus

RBE (relativebiologicaleffectiveness)correspondsto theratio of x- or -ray absorbed
dose(Gy) to thatof a modality(Gy(RBE))to obtainthe samebiologicalendpoint. A
RBE valueof 1.1is consideredfor protons[19].
TPS-name, an in-house treatment planning software (TPS) with multi-criteria
optimization(MCO) wasused.PMRT plansuseda PBSfield at a given gantryangle
(30 from vertical). Beamspotswere placedon a fixed-size grid, extending15 mm
aroundthe assignedtarget volume, with spotsspacedat one sigma (spot size). In
depth,scanninglayerswerespacedby 0.8 × thedistal80 % Braggpeakwidth. Dueto
machine limitations, an 8 cm range shifter was used to appropriatelyreach the
superficialtargets.theinstitution’s clinical machinepresentsa 9 to 16 mm spotsizeas
a function of energy. Pareto-optimal plans were generatedto meet the given
constraints[20]. Finally, the set of Pareto-optimal planswerenavigatedto a desired
state.
2.3 Beamrangeuncertainty
Beam range uncertainty due to inaccurateCT HU to proton stopping power
conversionis alwaysa concernand the usualpracticeat the institution is to add an
extra 3.5 % to the beamrangeto headoff the potentialundershooting.For patients
withoutbreasti mplant,thechestwall targetvolumesareusuallyvery shallowwith the
requiredbeamrangeat 3 cm or less.The associateduncertaintyis thusonly arounda
6

millimeter and can be practically ignored,being comparableto uncertaintiesin CT
scanning,contouring, etc. For patientswith breastimplants, the deepertreatment
range required to reach the chest wall could result in significantly larger range
uncertaintiesand potentially overshootinto the lung and cardiactissues.Phantom
measurementswere therefore performedin order to accuratelyassessthe relative
protonrelativestoppingpowerratio (RSP)of theexactmaterialusedinsidethebreast
implant.During planning,the breastimplantswerecontouredandassignedthe exact
RSP value basedon thosephantommeasurements.
With the contributionfrom the
breastimplantsentirelyeliminated,theresultantrangeuncertaintycontainsonly those
from the real chestwall tissueandis thusthe sameas thosefor the chestwall only
treatments.The measurementtechniquesof determiningthe RSP values for the
variousimplantsanddetailedanalysisof thedatawill bereportedseparately.
Anotherpossiblesourceof rangeuncertaintyis the daily variationsin the positionof
the breast implant relative to the rest of the body. However, for patient with
reconstructivesurgery,only thosewith breastimplantswereallowedfor PBSPMRT
dueto theextremelylimited mobility of suchimplants.
2.4 Skin dose
Unlike photonbeams,protonbeamsdo not havedosebuild upsat the skin surface.It
is naturally a concern if proton PMRT could increasechest wall skin toxicity,
althoughno suchincreasewasobservedfor the first grouppatientstreatedby passive
7

scattering[18]. With PBS,theskin dosecanbecontrolledasoneof theobjectives,as
shown above,in the Paretooptimization and navigation.In order to validate the
accuracyof the dosecalculationat the skin surface,we performedmeasurements
for
two treatmentfields generatedon a solid water phantom:one mimicking a nonreconstructedchest wall treatmentwith 3 cm beam range,and one mimicking a
treatmentwith breast implant with 8 cm range. The accuracyof the skin dose
calculationwasthenassessed
usinga Markusparallelplateion chamber.
2.5 Treatment delivery
the institution’s routine patientquality assurance(QA) procedurefor PBS treatment
was followed for these PMRT plans. Each PBS field was verified in phantom
measurementby an absolute point dose and 2D distributions at two different
depths[21].
the institution’s conventionalproton setupprocessconsistsof: first, the patient is
positionedbasedon tattoospriorly inkedat thetime of CT-sim; orthogonalX -raysare
thentakenat a specifiedcardinalangle,andthe patientpreciselyplacedat isocenter;
finally, a beamlineX-ray is performedat the treatmentgantry angleto finalize the
setuppositionandensurecorrecttreatment.This techniquewasunfortunatelydeemed
suboptimalfor PMRT patientsasit considersbonyanatomicalfeaturesin the backof
the patients,suchas the spine,as a surrogatefor the chestwall position[22]. This
resultedin the choice of surfaceimaging as the primary setup tool as the target
8

volumeis both shallowandsuperficial. In our process,the patientis first setupbased
on tattoosinkedat thetime of CT scan.A surfaceimagingsystem(brand),usingthree
camerasmountedin a typical triangularpatternas for a LINAC treatmentroom, is
then usedto position the patient at isocenter.Shifts are performedusing the couch
with 6-degreeof freedombasedon the treatmentplanningCT asthe referenceimage.
This referenceprovidesthe ability to monitor any anatomicaldeformationover the
courseof treatment.In oneexemplary case,a shift of the breastimplantwasdetected
andtheneedfor replanningwasassessed
throughtheacquisitionof a newCT scan.In
order to minimize the effect of breathingmotion on patientpositioning,the motion
tracking function of the surfaceimaging systemwas utilized and the body surface
correspondingto exhalelevel was selectedfor position correctioncalculations.The
operation tolerancelimits for the setup were 2 mm in translationsand 1.5 in
rotations.Then, a beamlineX-ray is taken at the treatmentgantry angle (30 from
vertical) asa final verification,primarily basedon threeradio-opaquemakersplaced
aroundthe patient’schestwall at positionsselectedand tattooedat the time of CT.
TheX-ray setuptolerancewas1.5mm.This is in considerationof thefact theX-ray is
not gatedto any specificbreathinglevel. For a typical breastpatient,the chestwall
moves about 3 mm in the AP/longitudinal direction at quiet respiration,which
projectsto a motionof 1.5 mm in thebeam’s eyeview with gantryangleat 30 from
vertical. This setup process combining surface and X-ray imaging has been
extensivelystudiedfor a large numberof patients.The full setupprocessgenerally
9

takes10 to 15 minutes.Surfaceimagingresultsin faster and more accuratepatient
positioning, along with minimal imaging dose (only final beamlineX-ray). The
techniques and detailed analyses of the results will be reported separately.
The single PBS treatmentfield usually contains10 to 15 layers with

2 s layer

switchingtime,resultingin a 2 min total beamdeliverytime.
2.6 Treatment robustnessevaluation
The treatmentrobustnesswasevaluatedagainsttwo typesof treatmentperturbations:
breathingmotion and setupuncertainties.For breathingmotion, a 4D-CT scanwas
performedfor a PMRT patientin additionto the regularplanningCT scanat quiet
respiration.Themotionof the chestwall dueto breathingwasfoundmostlyin theAP
direction as expectedwith the maximum amplitudeof 3 mm, which is typical of
breastpatients.The PBS fields generatedon the planning CT scan for the actual
treatmentweretransferredto the 4D CT scanwith dosedistributionsrecomputedon
eachof the10 phases.Dosevolumehistograms(DVH) werecomputedfor eachof the
10 phasesas well as for the total doseaccumulatedthroughdeformableregistration
[23], mimicking the actual treatment based on the patient’s breathing cycle.
The setupuncertaintiesanalysiswasperformedby recomputingthedosedistributions
for a nominal PMRT plan with the samePBS fields but with the introductionof
geometricperturbationsin the isocenterposition and patient body orientation.The
perturbationswereasfollow: ± 3 mm alongeachtranslationaxis(lateral,longitudinal,
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vertical),± 2 along eachrotation axis (yaw, pitch, roll), and a combinationof all
aforementionedshifts in all 6 directionssimultaneously.DVH were computedfor
eachscenario. The magnitudeof theseperturbationswasselectedin considerationof
the geometricaccuracyof the surfaceand X-ray imaging systems,as well as their
operationaltolerancesadoptedduringpatientsetup.
3 Results
3.1 Treatment plan quality
As a result of the multi-criteria optimization,the target coverageand doseto the
cardiacstructuresareoptimally balancedthroughintensitymodulation.Likewise,it is
possible to reduce the skin dose to an acceptablelevel, especially in the
supraclavicularnodal region, which is locateddeeperin the body. A nominal PBS
PMRT planis presentedin figure 2.
The dosestatisticsfor the left-sidedPBSPMRT patientstreatedin the first 4 months
of 2014(in total of 10) at theinstitutionarepresentedin table1.
3.2 Skin dosevalidation
Measurements
wereperformedwith a Markusparallelplateionizationchamberat 0,
1, 3, 5, and 7 mm depth, as well as in the center of the field (13 and 43 mm
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respectively),for both aforementionedtreatmentplans.The resultsare presentedin
figure 3. Thosemeasurements
werein goodagreement( 2 %) with theTPSvalues.
3.3 Treatment plan robustness
The robustnessanalysisresultsagainstsetupuncertaintiesarepresentedin figure 4 as
DVH envelopeswhich correspondto the maximum amplitudeof the perturbation
associatedwith thespecifiedshifts,individually or simultaneously.As laterdiscussed,
this can be considereda worst casescenario,and any combinationof shifts (± 3
mm,± 2 ) will be containedwithin thoseDVH boundaries.The DVH of the average
distributionbasedon all theseshifts is presentedas a thick dashedline. Overall, the
target coveragefor chest wall, supraclavicular/axilla nodal regions remainsquite
stable,andis thereforerobustagainstsetupuncertainties.Coverageof IMN deviates
substantially more from these shifts, although the minimum dose is still 40
Gy(RBE),evenin theworstcasescenario.ConcerningOARs,DVH distributionsvary
more for thyroid and esophagusthan for others,but all of them are still considered
clinically acceptable.
Theresultsfor robustnessanalysisagainstbreathingmotionareshownin figure 5. As
in figure 4, the DVH envelopescorrespondto the maximal deviationsbased on the
doserecomputationfor eachindividual breathingphase.Thesedeviations,drastically
smaller than the ones observedin the robustnessanalysisfor setup uncertainties
(figure4), arebelievedto be of no clinical concern.Moreover,it is admittedthat the
12

actual treatment would be approximately at the median of these envelopes
statistically,henceremarkablyclose to the planneddosefor the caseillustratedin
figure 5, ashighlightedby the averagedosedistributionDVH basedon the individual
recompuations(thick dashedline).
4 Discussions
PMRT for patientswith potential IMN involvement and yet unfavorablecardiac
anatomy is always a challenge to perform with both acceptable/reliabletarget
coverageand critical organ avoidance.Whereasit is necessaryto consider3 to 5
fields in photon/electrontherapy,or a minimum of 2 proton PS fields, in order to
appropriatelycover the numeroustargets,a single PBS field is sufficient. In the
absenceof matchedfields, this highly simplifies the treatmentdelivery andremoves
the hot and cold spots by meansof intensity modulation.Although the treatment
offersexcellentcardiacstructuresparing,theIMN receiveson averagea meandoseof
48.75 Gy(RBE) for the 10 abovementionedpatients.This representssignificantly
bettertargetcoverage,yet betterOAR sparing,thanconventionaltherapy[16].
For PMRT by PS,certainsmall areasof skin may receivethe full prescriptiondose
dueto thefixed modulationwidth of thepassivescatteredbeams.Early resultsfor PS
PMRT patients,however,did not showworseskin reactionsthanfor conventionalX ray treatment;contrarily, more often superficial dry, rather than moist, squamous
desquamationwereobserved.Predictedrednessof the skin within the treatmentfield
13

wasalsonoted[18]. With intensitymodulation,PBSallowsoneto minimizethedose
to the skin while maintaining a uniform target constraint. Given the positive
experiencewith PStreatment,patientsareexpectedto toleratePBStreatmentsequally
well, if not better.It is satisfactoryto seethat the planning systemcan accurately
computethe skin dose,as confirmedby the phantommeasurement.
Patientspecific
skin dose monitoring is currently under assessmentat the institutionusing
thermoluminescent
dosimeters[24], aswell asMOSkindetectors[25].
At the institution, PBS fields for chest wall treatmenttake significantly longer to
deliverthanconventionalscatteredfields: about5 minutesversus1 minute.However,
theoveralltreatmenttime,thatis thepatient-in-roomtime,usingPBSis only about15
to 18 minutes,muchshorterthanPStreatment.This is alsogenerallyshorterthanthe
conventionaltreatmentwith 4 photon/electronbeams,which takesabout25 minutes
evenwithout any form of imagingguidance.Optimizationof the currentworkflow is
still undergoingfor combineduse of surface and beamlineX-ray imaging, which
couldfurtherreducethesetuptime.
Theplanrobustnessanalyseswereperformedfor a singlepatientonly. Sincethebeam
directionandpatient’ssetupconfigurationaregenerallysimilar, solelytheanatomical
changeswould significantlyaffecttheseresults.This will be characterizedin a future
detailedstudyusinga largercohortof patients. It shouldbe notedthat the magnitude
of the shiftsandrotationsweredeliberatelylargein orderto testworst casescenarios
14

while, in reality, the setup uncertaintiesare statistically much smaller. This was
highlightedby the averagedosedistribution DVH in the robustnessanalysis.It is
important to point out that the plan robustnessanalysispresentedhere is closely
associatedwith the spotsizesof our currentPBS delivery systemand could change
for different beamspotsizes.It is generallytrue that PBStreatmentplanningquality
could differ per institution. Indeed, spot size, source-to-axis distance (SAD),
minimum deliverablecharge,and speed/accuracy
of treatmentdelivery are highly
machine specific parameters;besides, the institution’s TPS would dictate the
possibilities regardingspot spacing,layer spacing,and the overall quality of the
optimization(notably throughthe presenceor absenceof MCO). Major efforts are
currently underwayat the institutionto reduce the beam spot sizes for all beam
energies

including

those

relevant

to

chest

wall

treatment.

A theoreticalplan, presentingsignificant improvement
s over the plan presentedin
figure 2, was producedusing a 3 to 5 mm spot size. A smaller beam spot size,
however,could meana longertreatmenttime. It may alsodegradethe robustnessof
plan againstsetupuncertaintiesand breathingmotion. The implicationsof the spot
size changesand the properbalancebetweenall its effectswill be the subjectsof
futurestudies.
Oneof the mostinterestingpotentialimprovementsof PMRT usingprotontherapyis
thepossibilityof treatingthepatientswith their armsdownduringtreatmentasshown
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in figure1(b). Sucha setuppositionis unachievablefor conventionalphotontherapy
which usestangentfields that would treat throughthe arms. The rationalefor such
positionis basedon severalpromisingaspects.For one,it is muchmorecomfortable
thanthe arm up positionfor patientswith shouldermobility issuesdueto immediacy
of their surgery,scaring,andotherreasons.Second,patientswith armsup often feel
tired and relax their armsdownwards,potentiallyaffecting treatmentto the axillary
nodal regions,while more comfortablearm down position will result in the patient
stayingstill for a longer periodof time. Third, the arm down position allows larger
clearancebetweenthe patient and the treatmentnozzle,hencereducingthe risk of
hazardouscollision. It could also allow the use of smaller air gaps betweenthe
treatmentheadandthe patientto help maintainthe spotsizeandimprovethe overall
penumbraof thedosedistribution.We haverecentlytreateda patientin thearmdown
positionandarecurrentlycollectingdatafor morepatientsin orderto systematically
assessthis armsdownsetup.
Although one canforeseeinterplayeffectsbetweenthe beammotion andthe patient
internal motion for such treatment,theseeffects are considerednegligible at the
institutionbasedon previouswork on lungtreatmentplanning[26].
5 Conclusion
We havedevelopeda treatmenttechniquefor PMRTusingpencilbeamscanningwith
intensity modulation.More than 25 PMRT patientshave beensuccessfullytreated
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at the institution. This treatmenttechniqueis significantly simplerthan conventional
techniqueswhich usea combinationof photonandelectronbeams,yet with improved
nodalcoverageand significantly lesscardiacdose.Although this treatmentrelieson
full imageguidancewith surfaceand X-ray imaging, it is faster than conventional
techniques. There are on-going efforts to reachthe optimal PBS PMRT treatment
delivery.Futurestudieswill focuson specificaspectsof the presentedmethodology,
as well as the short-term side-effects and clinical outcomesof such PBS PMRT
treatment.
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Figure 5: Breathingmotion effect onto a static PMRT dosedistribution.The solid lines
representthe planneddosewhile the envelopescorrespondto themaximaldeviations
observedfrom the individual doserecomputationson the 10 phasesof the patient4D
scan,andthe thick dashedlines is the averagedosedistributionDVH basedon all 10
recomputations.
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Figure1: PMRTpatient setupat the time of CTscan:(a) conventionalarms up setupposition,(b) novelarms
down setup position; in both cases,a chin strap and hand grips are used for positioning reproducibility.

Figure2: A proton PBSPMRTplanand its associateddose-volumehistograms(DVH),asintendedfor treatment
at

the

institution.

Mean (cGy(RBE))

D99 (cGy(RBE))

D1 (cGy(RBE))

Target/OAR

Average

std dev.

Average

std dev.

Average

std dev.

IMN

48.71

1.71

44.30

2.47

51.25

1.28

IMN)

47.39

1.08

42.18

1.93

51.36

1.06

LAD

1.10

0.48

0

-

3.50

0.71

Heart

0.63

0.32

0

-

11.40

5.11

Chestwallskin

47.86

1.09

40.88

2.68

49.57

0.88

Lymphnodes(inc.

Table 1: Dosestatisticsfor 10 PBSPMRT patientstreatedat theinstitution; D99 andD1 arethe
dosesin Gy(RBE)receivedby 99 % and1 % of thetarget/OARvolume,respectively.

Figure 3: Skin dose comparisonbetween TPS-name computed valuesand Markus parallel plate ionization
chambermeasurements.

Figure4: ResultingDVHenvelopesbasedon the setuprobustnessanalysis(± 3 mm, ± 2) performedon a PMRT
patient plan (solidline), and comparedto the averagedosedistribution DVH(thick dashedline) basedon the
individualrecompuations.

Figure5: Breathingmotion effect onto a static PMRTdosedistribution.Thesolid lines representthe planned
dose while the envelopes correspond to the maximal deviations observed from the individual dose
recomputationson the 10 phasesof the patient 4D scan, and the thick dashedlines is the averagedose
distributionDVHbasedon all 10 recomputations.

